MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Seres Therapeutics Inc

Închisă

SectorSănătate

0.68 1.49

Rezumat

Modificarea prețului

24h

Curent

Minim

0.66

Maxim

0.69

Indicatori cheie

By Trading Economics

Venit

-104M

-16M

EPS

-0.11

Angajați

103

EBITDA

35M

-15M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+708.82% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-4.8M

126M

Deschiderea anterioară

-0.81

Închiderea anterioară

0.68

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Seres Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iun. 2024, 10:30 UTC

Achiziții, Fuziuni, Preluări

Seres Therapeutics Enters Into Memorandum of Understanding for Vowst Asset Sale to Nestlé Health Science

Comparație

Modificare preț

Seres Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

708.82% sus

Prognoză pe 12 luni

Medie 5.5 USD  708.82%

Maxim 10 USD

Minim 1 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSeres Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 0.72Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.